AQR Capital Management LLC Has $4.42 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

AQR Capital Management LLC grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 19.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 154,216 shares of the specialty pharmaceutical company's stock after acquiring an additional 25,206 shares during the period. AQR Capital Management LLC owned about 0.48% of Collegium Pharmaceutical worth $4,418,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Invesco Ltd. increased its stake in Collegium Pharmaceutical by 19.5% in the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after purchasing an additional 289,335 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after acquiring an additional 64,958 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Collegium Pharmaceutical by 0.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock valued at $47,603,000 after buying an additional 5,480 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Collegium Pharmaceutical by 5.6% during the 4th quarter. Northern Trust Corp now owns 385,157 shares of the specialty pharmaceutical company's stock worth $11,035,000 after buying an additional 20,490 shares during the last quarter. Finally, Royce & Associates LP grew its position in shares of Collegium Pharmaceutical by 11.0% in the fourth quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company's stock valued at $9,728,000 after purchasing an additional 33,674 shares during the last quarter.

Insider Buying and Selling

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 977 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $29,310.00. Following the transaction, the chief financial officer now directly owns 164,269 shares in the company, valued at $4,928,070. This represents a 0.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $28.50, for a total transaction of $742,909.50. Following the sale, the executive vice president now directly owns 108,137 shares in the company, valued at $3,081,904.50. This trade represents a 19.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,693 shares of company stock valued at $2,334,994 over the last quarter. 2.51% of the stock is currently owned by insiders.

Collegium Pharmaceutical Trading Up 0.8%

Shares of COLL traded up $0.24 during trading hours on Tuesday, reaching $29.80. 308,583 shares of the company traded hands, compared to its average volume of 434,076. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $42.29. The firm has a market cap of $957.53 million, a price-to-earnings ratio of 12.84 and a beta of 0.63. The stock's fifty day moving average price is $28.12 and its 200 day moving average price is $29.97. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). The firm had revenue of $177.76 million during the quarter, compared to analysts' expectations of $174.96 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm's quarterly revenue was up 22.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.45 EPS. Sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on COLL. Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 price objective (up from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday. StockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $43.80.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.